Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.1 (
chymotrypsin
)
10,938
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Quinidine-induced thrombocytopenia has been associated with both immune complex and autoantibody binding to platelets. In the present study, serum antibody from six of six patients with quindine purpura was shown by immunoblotting to bind to a single platelet membrane protein of mol wt 80,000. This target protein was absent from Bernard-Soulier (BSS) platelets. F(ab)2 prepared from one patient's serum also bound to this protein, indicating autoantibody rather than immune complex binding to the target antigen. Antibody binding to the 80-kd protein was preserved after treatment of platelets with concentrations of trypsin or
chymotrypsin
that completely removed glycoprotein Ib (GPIb). Preincubation of platelet proteins with one patient's serum blocked binding of a polyclonal rabbit antibody against
glycoprotein V
(
GPV
), indicating that these antibodies recognize the same antigen. By wheat germ affinity chromatography,
GPV
was shown to copurify with GPIb. Quinidine-induced antibody bound to the wheat germ-purified
GPV
but not to GPIb. We conclude that quinidine purpura is associated with autoantibody directed against platelet
GPV
.
...
PMID:Quinidine purpura: evidence that glycoprotein V is a target platelet antigen. 293 47
Human platelets were surface-labeled by the periodate/NaB3H4 method or by lactoperoxidase-catalysed iodination with 125I. The labeled platelets were treated with
chymotrypsin
under conditions known to give platelets which aggregate with fibrinogen without stimulation with ADP. Platelets and supernatant were then analysed by various gel electrophoretic techniques including isoelectric focusing/sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing or non-reducing conditions and two-dimensional non-reduced/reduced sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by fluorography or indirect autoradiography. Chymotrypsin-treatment of surface-labeled platelets degraded the major glycoproteins Ib, IIb and IIIa but also GP120(4.9-5.4), GPIc and
GPV
. The membrane-bound fragments of GPIb, IIb and IIIa could be identified and also the supernatant fragments of GPIb and
GPV
. GPIIIa was also cleaved within a loop structure formed by disulfide bond(s). The fact that remnants of both GPIIb and IIIa are left on
chymotrypsin
-treated platelets which aggregate spontaneously with fibrinogen may indicate that a complex formed by these remnants constitutes the fibrinogen-binding site on platelets.
...
PMID:Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment. 397 99
To assess the possibility that hydrolysis of the platelet surface thrombin substrate,
glycoprotein V
, is a necessary step in thrombin-induced platelet activation, thrombin-catalyzed hydrolysis of
glycoprotein V
was correlated with thrombin-induced platelet activation. Hydrolysis of tritium-labeled
glycoprotein V
on washed human platelets was measured by the appearance of a labeled supernatant fragment, and platelet activation was measured as secretion of ATP. Hydrolysis of
glycoprotein V
was linear with respect to both thrombin concentration and time of incubation. The extent of platelet activation was correlated with the rate of hydrolysis but not with the amount hydrolyzed. Maximum platelet activation could be obtained with thrombin treatments resulting in hydrolysis of as little as 4% of
glycoprotein V
per min. Glycoprotein V was partially removed from platelets by pretreatment with either platelet calcium-dependent protease or
chymotrypsin
. The rate of thrombin-catalyzed hydrolysis of the remaining
glycoprotein V
from these pretreated platelets was as little as 1.5% the rate from control platelets, but there was no impairment of the extent of platelet activation. Thus, these protease-pretreated platelets compared with control platelets showed a different correlation of
glycoprotein V
hydrolysis with platelet activation. Glycoprotein V was also partially removed by pretreatment of prostacyclin-inhibited platelets with thrombin. After removal of thrombin and prostacyclin, these platelets were desensitized to subsequent activation by thrombin. Incubation of desensitized platelets with nonsaturating levels of thrombin led to less than 25% of the activation seen with control platelets but to a slightly greater hydrolysis of
glycoprotein V
. Thus, the desensitization to thrombin was not due to loss of ability of the activating thrombin to hydrolyze
glycoprotein V
. These results do not exclude a role for
glycoprotein V
as a component of the platelet thrombin receptor, but they indicate that there is no simple relationship between thrombin-induced hydrolysis of
glycoprotein V
and platelet activation.
...
PMID:Correlation of thrombin-induced glycoprotein V hydrolysis and platelet activation. 630 38